Gilead Sciences: Industry Landscape, Strong Growth Make It a Buy Gilead Sciences (GILD) is one of the leading biopharmaceutical companies, providing innovative therapeutics in areas of unmet medical needs.With the mission to advance the care of patients suffering from life-threatening diseases, Gilead...
Gilead Q2 Profit Rises On Higher Sales Of AIDS Drugs (RTTNews) - Drug maker Gilead Sciences Inc.(GILD) Thursday reported an 8.56% increase in second-quarter profit on higher sales of HIV drugs Atripla and Truvada, combined with a favorable currency exchange rate.
Earnings, however, missed...
Gilead Q2 Profit Rises On Higher Sales Of AIDS Drugs (RTTNews) - Drug maker Gilead Sciences Inc.(GILD: News, Chart, Quote ) Thursday reported an 8.56% increase in second-quarter profit on higher sales of HIV drugs Atripla and Truvada, combined with a favorable currency exchange rate.
Gilead Q2 Profit Rises On Higher Sales Of AIDS Drugs (RTTNews) - Drug maker Gilead Sciences Inc.(GILD | Quote | Chart | News | PowerRating) Thursday reported an 8.56% increase in second-quarter profit on higher sales of HIV drugs Atripla and Truvada, combined with a favorable currency...
Gilead Sciences Announces Second Quarter 2008 Financial Results - Record Total Revenues of $1.28 Billion, Up 22 Percent over Second Quarter 2007 - - Record Product Sales of $1.22 Billion, Up 34 Percent over Second Quarter 2007 - - Second Quarter EPS of $0.46 per Share - - Second Quarter Non-GAAP EPS of ...
Gilead 2Q profit rises on HIV drug sales FOSTER CITY, Calif.- Biotechnology company Gilead Sciences Inc.
said Thursday its second-quarter profit rose 9 percent on sales of its HIV drugs Atripla and Truvada, which currently dominate the market.
The company earned $442.8...
Gilead 2Q profit rises on HIV drug sales Biotechnology company Gilead Sciences Inc.said Thursday its second-quarter profit rose 9 percent on sales of its HIV drugs Atripla and Truvada, which currently dominate the market.
The company earned $442.8 million, or 46 cents per...
Gilead 2Q profit rises on HIV drug sales Biotechnology company Gilead Sciences Inc.said Thursday its second-quarter profit rose 9 percent on sales of its HIV drugs Atripla and Truvada, which currently dominate the market.
The company earned $442.8 million, or 46 cents per...
Gilead Sciences' 2nd-quarter profit rises on sales boosts for HIV drugs Atripla, Truvada FOSTER CITY, Calif.(AP) - Biotechnology company Gilead Sciences Inc.
said Thursday its second-quarter profit rose 9 percent on sales of its HIV drugs Atripla and Truvada, which currently dominate the market.
The company earned $442.8...
Gilead 2Q profit rises on HIV drug sales FOSTER CITY, Calif.(AP) - Biotechnology company Gilead Sciences Inc.
said Thursday its second-quarter profit rose 9 percent on sales of its HIV drugs Atripla and Truvada, which currently dominate the market.
The company earned $442.8...
Earnings Preview: Gilead Sciences OVERVIEW: Demand for the company's HIV treatments remains strong, based on sales estimates from IMS Health during the quarter.Gilead gets most of its revenue from Truvada, which is a mix of its Viread and Emtriva treatments, and Atripla,...
Earnings Preview: Gilead Sciences OVERVIEW: Demand for the company's HIV treatments remains strong, based on sales estimates from IMS Health during the quarter.Gilead gets most of its revenue from Truvada, which is a mix of its Viread and Emtriva treatments, and Atripla,...
Hepatitis B is a more serious infection of the liver than Hepatitis A discussed last week.Hepatitis B is one of 6 currently identified strains of viral hepatitis.
The others are A,C,D,E and G and each strain is unique differing in presentation and...
Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Age 96-week comparative study of Clevudine versus Viread(R) versus Clevudine+Viread(R) in 150 patients with chronic hepatitis B PRINCETON, N.J., July 8 /PRNewswire-FirstCall/ -- The French National Agency for Research on AIDS and Viral Hepatitis...
Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Age 96-week comparative study of Clevudine versus Viread(R) versus Clevudine+Viread(R) in 150 patients with chronic hepatitis B PRINCETON, N.J., July 8 /PRNewswire-FirstCall/ -- The French National Agency for Research on AIDS and Viral Hepatitis...
Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Age PRINCETON, N.J., July 8 /PRNewswire-FirstCall/ -- The French National Agency for Research on AIDS and Viral Hepatitis (ANRS), with the support of Pharmasset, Inc.(Nasdaq: VRUS) and Gilead Sciences, Inc.
(Nasdaq: GILD), has initiated the...
Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Age PRINCETON, N.J., July 8 /PRNewswire-FirstCall/ -- The French National Agency for Research on AIDS and Viral Hepatitis (ANRS), with the support of Pharmasset, Inc.(Nasdaq: VRUS) and Gilead Sciences, Inc.
(Nasdaq: GILD), has initiated the...
Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Age PRINCETON, N.J., July 8 /PRNewswire-FirstCall/ -- The French National Agency for Research on AIDS and Viral Hepatitis (ANRS), with the support of Pharmasset, Inc.(Nasdaq: VRUS) and Gilead Sciences, Inc.
(Nasdaq: GILD), has initiated the...
Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Age PRINCETON, N.J., July 8 /PRNewswire-FirstCall/ -- The French National Agency for Research on AIDS and Viral Hepatitis (ANRS), with the support of Pharmasset, Inc.(Nasdaq: VRUS) and Gilead Sciences, Inc.
(Nasdaq: GILD), has initiated the...
Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Age PRINCETON, N.J., July 8 /PRNewswire-FirstCall/ -- The French National Agency for Research on AIDS and Viral Hepatitis (ANRS), with the support of Pharmasset, Inc.(Nasdaq: VRUS) and Gilead Sciences, Inc.
(Nasdaq: GILD), has initiated the...
Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Age PRINCETON, N.J., July 8 /PRNewswire-FirstCall/ -- The French National Agency for Research on AIDS and Viral Hepatitis (ANRS), with the support of Pharmasset, Inc.(Nasdaq: VRUS) and Gilead Sciences, Inc.
(Nasdaq: GILD), has initiated the...
Entecavir Boosts Hepatitis B Response After Lamivudine Failure TORONTO, July 1 -- Patients who were lamivudine (Epivir) refractory saw improved hepatitis B suppression that lasted through almost two years of treatment with entecavir (Baraclude).The percentage of patients with fewer than 300 HBV DNA...
Push for more HIV screens to drive Gilead's growth According to the Associated Press, increasing efforts by U.S.cities such as New York to expand HIV testing will boost Gilead Sciences' bottomline, since more than 80 percent of the nation's newly diagnosed HIV patients begin treatment...
IP for Business: The Fall and Rise of Pharma Brand Names On a roll.Brand creation experts are coming up with a new generation of names for pharmaceutical products to help shape attitudes towards the industry and appreciation for its innovations.
(photos.com) Whats in a name?
Sometimes the...
Push for more HIV screens to drive Gilead's growth Increasing efforts by U.S.cities such as New York to expand HIV testing will boost Gilead Sciences' bottomline, since more than 80 percent of the nation's newly diagnosed HIV patients begin treatment with either the company's Truvada or...
